RenovoRx, Inc. (RNXT)
1.67
+0.19
(+12.84%)
USD |
NASDAQ |
Aug 28, 16:00
1.70
+0.03
(+1.80%)
After-Hours: 20:00
RenovoRx Enterprise Value : 66.26M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 66.26M |
| August 27, 2026 | 57.69M |
| August 26, 2026 | 58.14M |
| August 25, 2026 | 54.98M |
| August 24, 2026 | 47.31M |
| August 21, 2026 | 50.47M |
| August 20, 2026 | 50.47M |
| August 19, 2026 | 50.25M |
| August 18, 2026 | 43.70M |
| August 17, 2026 | 45.06M |
| August 14, 2026 | 54.08M |
| August 13, 2026 | 47.76M |
| August 12, 2026 | 41.45M |
| August 11, 2026 | 42.80M |
| August 10, 2026 | 43.25M |
| August 07, 2026 | 41.45M |
| August 06, 2026 | 42.80M |
| August 05, 2026 | 38.74M |
| August 04, 2026 | 37.84M |
| August 03, 2026 | 38.74M |
| July 31, 2026 | 34.15M |
| July 30, 2026 | 33.38M |
| July 29, 2026 | 31.44M |
| July 28, 2026 | 31.85M |
| July 27, 2026 | 34.46M |
| Date | Value |
|---|---|
| July 24, 2026 | 29.96M |
| July 23, 2026 | 29.47M |
| July 22, 2026 | 29.96M |
| July 21, 2026 | 30.51M |
| July 20, 2026 | 29.88M |
| July 17, 2026 | 29.96M |
| July 16, 2026 | 30.66M |
| July 15, 2026 | 29.70M |
| July 14, 2026 | 29.26M |
| July 13, 2026 | 32.13M |
| July 10, 2026 | 32.88M |
| July 09, 2026 | 33.32M |
| July 08, 2026 | 31.52M |
| July 07, 2026 | 32.76M |
| July 06, 2026 | 33.67M |
| July 02, 2026 | 32.43M |
| July 01, 2026 | 34.01M |
| June 30, 2026 | 35.13M |
| June 29, 2026 | 31.53M |
| June 26, 2026 | 30.34M |
| June 25, 2026 | 29.72M |
| June 24, 2026 | 30.76M |
| June 23, 2026 | 28.85M |
| June 22, 2026 | 28.83M |
| June 18, 2026 | 29.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Enanta Pharmaceuticals, Inc. | 388.57M |
| Travere Therapeutics, Inc. | 6.312B |
| REGENXBIO, Inc. | 667.94M |
| Krystal Biotech, Inc. | 9.565B |
| ACADIA Pharmaceuticals, Inc. | 4.128B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.911M |
| Revenue (Quarterly) | 0.909M |
| Total Expenses (Quarterly) | 3.82M |
| EPS Diluted (Quarterly) | -0.0616 |
| Gross Profit Margin (Quarterly) | 84.27% |
| Profit Margin (Quarterly) | -320.2% |
| Earnings Yield | -18.80% |
| Normalized Earnings Yield | -19.78 |